Lantern Pharma Inc.
LTRN
$3.16
-$0.03-0.94%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -19.88M | -20.78M | -19.09M | -17.75M | -17.53M |
| Total Depreciation and Amortization | 197.80K | 149.50K | 262.50K | 218.30K | 175.50K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 392.70K | 590.40K | -191.40K | 344.60K | 792.00K |
| Change in Net Operating Assets | 166.50K | 2.23M | 1.79M | 1.93M | 2.91M |
| Cash from Operations | -19.12M | -17.81M | -17.23M | -15.26M | -13.66M |
| Capital Expenditure | -11.60K | -12.60K | -14.60K | -16.40K | -12.10K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 7.18M | 3.38M | 192.90K | -254.00K | -513.40K |
| Cash from Investing | 7.16M | 3.37M | 178.20K | -270.40K | -525.50K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 12.00K | 66.70K | 66.70K | 54.70K | 54.70K |
| Repurchase of Common Stock | -- | -- | -500.00K | -500.00K | -500.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 12.00K | 66.70K | -433.30K | -445.30K | -445.30K |
| Foreign Exchange rate Adjustments | -36.90K | -49.50K | 12.90K | -15.50K | -33.20K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -11.98M | -14.43M | -17.47M | -15.99M | -14.66M |